AmacaThera, a clinical-stage biotechnology company specializing
in drug delivery, announced it has signed a binding evaluation and option
agreement with Merck Animal Health to develop long-acting formulations, for
use in animal health.
Read more
Amacathera Collaborates With Leading Global Pharmaceutical Company To Develop Single-Injection, Long-Acting Biologic Using Its Advanced Hydrogel Delivery Platform, Amacagel™ Read more
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey. Read more
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round. Read more
AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications. Read more
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™. Read more
AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma. Read more
In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation. Watch the animated explainer inside this article. Read more
In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a one-minute animation that outlines its approach to drug development. Read more
adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to join this year’s adMare Academy Executive Institute. Read more
Amacathera Inc. has been named a Canadian Innovation Exchange (CIX)’s Top 20 Early company for 2021. Read more
ICYMI: Thanks to CBC's Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet. Read more
Globe and Mail features AmacaThera’s Series A financing Read more
Clinical trials set to begin on their proprietary drug delivery platform addresses key problem in sustained therapeutic delivery and is applicable to numerous disease indications and therapeutic modalities. Read more
Biomedical engineer’s novel hydrogel designs useful for regenerative medicine. Read more
AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has already raised $3.25 million (CAD) in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners. Read more
Shoichet Will Help Accelerate Scientific Innovation and Advance Science in Government Decision-Making. Read more